

United Kingdom of Great Britain and Northern Ireland

Tuberculosis profile

Population 2013

63 million

Estimates of TB burden * 2013	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.34 (0.34–0.34)	0.54 (0.53–0.54)
Mortality (HIV+TB only)	0.012 (<0.01–0.02)	0.02 (0.01–0.03)
Prevalence (includes HIV+TB)	11 (4.4–20)	17 (6.9–32)
Incidence (includes HIV+TB)	8.3 (7.7–8.8)	13 (12–14)
Incidence (HIV+TB only)	0.098 (0.059–0.14)	0.15 (0.09–0.23)
Case detection, all forms (%)	89 (84–95)	

Estimates of MDR-TB burden * 2013	New	Retreatment
% of TB cases with MDR-TB	1.4 (1–1.7)	5.7 (3.2–9.4)
MDR-TB cases among notified pulmonary TB cases	52 (40–66)	17 (10–29)

TB case notifications 2013	New **	Relapse
Pulmonary, bacteriologically confirmed	2 807	
Pulmonary, clinically diagnosed	1 022	
Extrapulmonary	3 555	

Total new and relapse	7 384
Previously treated, excluding relapses	508
Total cases notified	7 892

Among 7 384 new and relapse cases:

311 (4%) cases aged under 15 years; male:female ratio: 1.4

Reported cases of RR-/MDR-TB 2013	New	Retreatment	Total **
Cases tested for RR-/MDR-TB	4 128 (147%)	250 (49%)	4 607
Laboratory-confirmed RR-/MDR-TB cases			86
Patients started on MDR-TB treatment			70

TB/HIV 2013	Number	(%)
TB patients with known HIV status		
HIV-positive TB patients		
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)		
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

Treatment success rate	(%)
New and relapse cases registered in 2012	80
Previously treated cases, excluding relapse, registered in 2012	72
HIV-positive TB cases, all types, registered in 2012	
RR-/MDR-TB cases started on second-line treatment in 2011	51
XDR-TB cases started on second-line treatment in 2011	0


Laboratories 2013	
Is second-line drug susceptibility testing available?	Yes, in country

Financing TB control 2014	
National TB programme budget (US\$ millions)	

* Ranges represent uncertainty intervals


** Includes cases with unknown previous TB treatment history

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population)




Prevalence

(Rate per 100 000 population per year)




Notified (new and relapse) Incidence
Incidence (HIV+TB only)

(Number of patients)



HIV-positive TB patients
on CPT on ART

Treatment success rate (%)



New Retreatment
New and relapse Retreatment, excluding relapse
HIV-positive RR-/MDR-TB XDR-TB